Who should Pfizer buy?

Biogen Idec's sudden step onto the sale block has set off a frenzy of buyout talk. Will Pfizer buy it? According to the Wall Street Journal, Pfizer considered a Biogen deal two years ago and passed. What about Biogen's crosstown rival Genzyme, whose stock jumped on the Biogen news because it's a biotech ripe for Big Pharma plucking? It might be a better fit for Pfizer, some analysts say. Pfizer, of course, isn't talking.

- here's more about Pfizer's pass on Biogen two years ago
- check out this speculation about a Pfizer-Genzyme marriage

ALSO: Who will buy Biogen Idec? Poll

Related Articles:
Biogen Idec in play after Icahn makes his move. Report
Boston officials herald big Genzyme expansion. Report
Pfizer-Sanofi match not made in heaven? Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Biogen Idec | Genzyme

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.